Morgan Stanley lowered the firm’s price target on Bristol Myers (BMY) to $36 from $37 and keeps an Underweight rating on the shares. The firm adjusted its large cap pharma and biotech models for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting season for the group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Trump plans to announce ‘major’ tariff on pharmaceutical imports, Reuters says
- Artiva CMO Thorsten Graef switches to advisor role, Subhashis Banerjee succeeds
- Bristol Myers says FDA approves Opdivo plus Yervoy as CRC treatment
- FDA approves nivolumab with ipilimumab for additional indication
- Bristol-Myers Squibb: Hold Rating Amid Patent Expirations and Uncertain Growth Path